Essential Microbiological Testing in Pharmaceuticals
Microbiological testing ensures the microbiological quality of pharmaceutical products. It is one of the most critical aspects of Good Manufacturing Practices (GMP). Microbial contamination can lead to product spoilage, reduced efficacy, and even severe health risks for patients. Therefore, microbiological testing plays a vital role throughout all stages of pharmaceutical production — from raw materials to finished products and manufacturing environments.
This article provides an overview of the key microbial tests performed in pharmaceutical industries, their purposes, applicable guidelines, and their importance in ensuring product safety and compliance.
List of Microbiological Testing in Pharmaceutical Manufacturing
Here is a comprehensive list of essential microbiological tests conducted in pharmaceutical manufacturing:
1. Microbial Limit Test (MLT)
What is this?
The Microbial Limit Test (MLT) is a microbiological quality test performed on non-sterile pharmaceutical products to determine the number and type of viable microorganisms (bacteria, yeasts, and molds) that may be present.
It helps ensure that the microbial content of the product is within the acceptable limits defined by pharmacopeial standards (USP, EP, JP, BP).
Purpose
-To quantitatively and qualitatively assess the microbiological quality of raw materials, intermediates, and finished products.
-To confirm that the product does not contain harmful or objectionable microorganisms.
-To ensure compliance with pharmacopeial standards for non-sterile products.
Tests Included
A. Quantitative Tests:
-Total Aerobic Microbial Count (TAMC) — measures total viable aerobic bacteria.
-Total Yeast and Mold Count (TYMC) — measures total viable fungi (yeasts and molds).
B. Qualitative Tests (Specified Microorganisms):
Detects the presence or absence of objectionable microorganisms such as:
-Escherichia coli
-Staphylococcus aureus
-Pseudomonas aeruginosa
-Salmonella spp.
-Candida albicans
-Clostridium spp. (for certain dosage forms)
Guidelines and References
The Microbial Limit Test must be conducted according to pharmacopeial and regulatory standards, such as:
| Reference | Section/Chapter | Description |
| USP <61> | Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests | For total microbial count |
| USP <62> | Tests for Specified Microorganisms | For detection of objectionable microorganisms |
| EP 2.6.12 | Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests | European guideline |
| EP 2.6.13 | Tests for Specified Microorganisms | European guideline |
| WHO TRS 1025 Annex 7 | Guidelines on Microbiological Testing of Non-sterile Products | WHO reference |
| ICH Q6A | Specifications: Test Procedures and Acceptance Criteria | Global quality standard |
Importance
–Ensures product safety by verifying that the microbial level is within pharmacopeial limits.
-Prevents product spoilage, discoloration, or odor changes caused by microbial growth.
-Protects patients from potential infections or toxic effects due to microbial contamination.
-Confirms GMP compliance and supports batch release decisions.
-Detects any cross-contamination or poor hygiene in the manufacturing environment.
When to Perform the Test?
| Stage | When MLT is Performed | Purpose |
| Raw Materials | Before use or upon receipt | To verify microbiological quality of raw ingredients |
| In-Process Samples | During manufacturing | To monitor bioburden and control contamination |
| Finished Products | Before batch release | To ensure product meets microbial specifications |
| Stability Samples | As per stability protocol (e.g., 3M, 6M, 12M) | To monitor microbial quality over shelf life |
| Environmental/Water Monitoring Samples | Routinely (daily/weekly/monthly) | To assess facility hygiene and control program |
2. Sterility Test
What is this?
The Sterility Test is a critical microbiological quality control test performed to ensure that sterile pharmaceutical products (such as injectables, ophthalmic preparations, and certain medical devices) are free from viable microorganisms (bacteria, fungi, or spores).
This test verifies the effectiveness of sterilization processes and the aseptic integrity of the product and its packaging.
Purpose
-To confirm that the product is sterile and safe for human use.
-To verify the efficiency of the sterilization method (e.g., autoclaving, filtration, dry heat).
-To detect any microbial contamination introduced during manufacturing, filling, or packaging.
-To ensure compliance with regulatory standards (WHO, USP, EP, BP, etc.) for sterile pharmaceuticals.
Tests Included
There are two principal methods used for sterility testing:
a. Membrane Filtration Method
-Used for filterable products (aqueous or oily solutions).
-The test sample is passed through a sterile membrane filter (0.45 μm or 0.22 μm) that traps any microorganisms.
The filter is then divided into two parts and incubated in:
–Fluid Thioglycollate Medium (FTM) – for anaerobic and aerobic bacteria
–Soybean Casein Digest Medium (SCDM or TSB) – for fungi and aerobic bacteria
b. Direct Inoculation Method
-Used for non-filterable products (ointments, creams, or powders).
-The product is directly inoculated into both FTM and SCDM media.
-The media are observed for turbidity (microbial growth) during the incubation period.
Guidelines and References
Sterility testing procedures and acceptance criteria are defined in the following regulatory standards:
| Regulatory Body / Standard | Reference Section / Chapter |
| United States Pharmacopeia (USP) | <71> Sterility Tests |
| European Pharmacopoeia (EP) | 2.6.1 Sterility |
| British Pharmacopoeia (BP) | Appendix XVI A |
| Japanese Pharmacopoeia (JP) | 4.06 Sterility Test |
| WHO Guidelines | TRS 1025, Annex 7 |
| ISO Standard | ISO 11737-2: Sterility Testing of Medical Devices |
Test Conditions
-Must be performed under Grade A laminar airflow cabinet in a Grade B cleanroom.
-Media sterility and growth promotion tests (GPT) must be validated before use.
-Positive and negative controls are required for validation of the method.
Importance
-Ensures that sterile products are free from microbial contamination, protecting patient safety.
-Confirms integrity of aseptic manufacturing processes.
-Prevents product recalls, regulatory actions, and adverse health events.
-A key requirement for regulatory approval and GMP compliance.
-Builds confidence in the sterilization validationand cleanroom environmental controlprograms.
When to Perform the Test?
| Stage / Product Type | Frequency / Timing |
| Finished sterile product | Every batch before release |
| Media validation (GPT, sterility of media) | Every new batch of media |
| Positive and negative control validation | With each sterility test run |
| Environmental monitoring of test area | During each sterility test |
| Method suitability testing | During product validation or whenever formulation changes occur |
Typical incubation period:
14 days total
FTM: 30–35°C (bacteria)
SCDM (TSB): 20–25°C (fungi and aerobic bacteria)
3. Bacterial Endotoxin Test (BET) / LAL Test
What is this?
The Bacterial Endotoxin Test (BET), commonly known as the LAL Test, is a microbiological assay used to detect and quantify endotoxins — toxic components of the outer membrane of Gram-negative bacteria.
Endotoxins are lipopolysaccharides (LPS) that can cause fever, shock, and other severe reactions when present in parenteral (injectable) or ophthalmic pharmaceutical products.
The test uses a reagent prepared from the amebocyte lysate of the horseshoe crab (Limulus polyphemus), which reacts specifically with endotoxins to form a clot or turbidity.
Purpose
-To ensure that parenteral, ophthalmic, and medical device products are free from harmful levels of bacterial endotoxins.
-To replace the Rabbit Pyrogen Test (RPT), providing a more ethical, sensitive, and reliable in-vitro alternative.
-To verify that water systems (WFI, Purified Water) and bulk pharmaceutical solutions meet endotoxin limits before use in sterile manufacturing.
Tests Included (Types of BET / LAL Methods)
There are three principal methods for detecting endotoxins using LAL reagent:
Gel-Clot Method
Qualitative (pass/fail) method.
Based on the formation of a gel clot in the presence of endotoxin.
Simple, cost-effective, but less quantitative.
Turbidimetric Method
Quantitative method that measures increase in turbidity (cloudiness) over time as the reaction occurs.
Results are expressed in Endotoxin Units (EU/mL).
Chromogenic Method
Quantitative method where a color change occurs due to the cleavage of a chromogenic substrate by enzymes activated by endotoxins.
The intensity of color is measured spectrophotometrically.
Guidelines and References
United States Pharmacopeia (USP) <85> — Bacterial Endotoxins Test
European Pharmacopoeia (EP) 2.6.14 — Bacterial Endotoxins
Japanese Pharmacopoeia (JP) 4.01
ICH Q6A — Specifications: Test Procedures and Acceptance Criteria
WHO TRS No. 1025 (Annex 7) — Sterile Pharmaceutical Products
FDA Guidance — “Pyrogen and Endotoxins Testing: Questions and Answers” (2012)
Importance
-Ensures patient safety by confirming the absence of pyrogenic (fever-inducing) substances.
-Prevents febrile reactions, septic shock, or multi-organ failure caused by endotoxin contamination.
-Protects the reputation and compliance of pharmaceutical companies under GMP and regulatory standards.
Required for:
-Parenteral products (injections, infusions)
-Ophthalmic solutions
-Water for Injection (WFI)
-Medical devices that come in contact with blood or cerebrospinal fluid.
When to Perform the Test?
| Stage / Sample Type | Testing Frequency / Time | Remarks |
| Water for Injection (WFI) | Daily / Per batch | To ensure water used in sterile manufacturing is endotoxin-free. |
| Bulk sterile solutions (before sterilization) | Each batch | To verify endotoxin levels are within acceptable limits before sterilization. |
| Finished sterile products | Each batch | Mandatory test before product release. |
| Cleaning validation rinse samples | As per validation protocol | Ensures no residual endotoxin contamination. |
| Media, equipment, and utilities | During qualification and requalification | Ensures aseptic integrity of manufacturing systems. |
Acceptance Criteria
Expressed as Endotoxin Units (EU/mL).
The maximum allowable endotoxin limit is determined by the formula:
Endotoxin Limit (EU/mL) =KM
Where:
K = threshold pyrogenic dose (typically 5 EU/kg for intravenous products)
M = maximum human dose per kg body weight per hour.
4. Antimicrobial Effectiveness Test (AET) / Preservative Efficacy Test (PET)
What is this?
The Antimicrobial Effectiveness Test (AET) — also called the Preservative Efficacy Test (PET) — is a microbiological test performed to evaluate the effectiveness of antimicrobial preservatives used in pharmaceutical, cosmetic, or personal care formulations.
These preservatives are added to prevent the growth of microorganisms that might be introduced during manufacturing, storage, or product use (especially in multi-dose containers).
The test challenges the product with known microorganisms and measures the reduction in viable counts over a specified time period.
Write a SOP following: SOP For Antimicrobial Effectiveness Test
Purpose
-To ensure that the preservative system in a formulation is effective enough to inhibit or kill microorganisms that may contaminate the product during storage or use.
-To confirm that microbial contamination does not exceed acceptable limits throughout the product’s shelf life.
-To verify compliance with pharmacopeial standards (USP, EP, BP, etc.).
Tests Included (Challenge Organisms)
The following five standard test microorganisms are used, representing bacteria, yeast, and mold:
| Microorganism | Type | Common Source / Importance |
| Staphylococcus aureus (ATCC 6538) | Gram-positive bacterium | Common contaminant from skin or handling |
| Pseudomonas aeruginosa (ATCC 9027) | Gram-negative bacterium | Common contaminant in aqueous solutions |
| Escherichia coli (ATCC 8739) | Gram-negative bacterium | Indicator of fecal contamination |
| Candida albicans (ATCC 10231) | Yeast | Common fungal contaminant |
| Aspergillus brasiliensis (formerly A. niger, ATCC 16404) | Mold | Represents filamentous fungi |
Note: Other microorganisms may be included depending on product type and regulatory requirement.
Guidelines and References
The AET/PET is described in major pharmacopeias and regulatory documents:
| Reference | Chapter / Section | Title |
| United States Pharmacopeia (USP) | <51> | Antimicrobial Effectiveness Testing |
| European Pharmacopoeia (EP) | 5.1.3 | Efficacy of Antimicrobial Preservation |
| British Pharmacopoeia (BP) | Appendix XVI A | Efficacy of Antimicrobial Preservation |
| WHO Technical Report Series (TRS 1025) | Annex 7 | Microbiological quality of non-sterile products |
| ICH Q6A | – | Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products |
Importance
-Ensures microbiological stability of the product throughout its shelf life.
-Confirms that preservatives protect against accidental contamination during use.
-Prevents microbial spoilage, color change, odor, or degradation of the product.
-Safeguards patient health by minimizing the risk of infection.
-Required for regulatory submission and product release approval.
Sampling Period
The test measures microbial reduction at specific time intervals after inoculation.
Sampling Schedule (Typical USP / EP Time Points):
| Time Point | Purpose |
| 0 hours | Initial microbial count (baseline) |
| 6 hours (optional) | Early activity (for fast-acting preservatives) |
| 24 hours | Short-term action |
| 7 days | Intermediate assessment |
| 14 days | Medium-term effectiveness |
| 28 days | Final evaluation (long-term preservation) |
Microbial counts are recorded at each interval and compared with the acceptance criteria defined by the relevant pharmacopoeia.
Acceptance Criteria (Log Reduction) differ for Category 1–4 products in USP/EP (e.g., injections, oral, topical, ophthalmic, etc.).
When to Perform the Test?
1. During Product Development (Formulation Stage)
Mandatory during the formulation development phase to evaluate whether the chosen preservative systemis effective in that specific formulation.
Conducted for each new product or formulation change, especially if:
-A new preservative is introduced
-Preservative concentration is modified
-pH or solvent system is changed
-Container–closure system changes (which might affect microbial exposure)
Purpose: To confirm the formulation meets pharmacopoeial acceptance criteria before moving to commercial production.
2. During Process Validation / Stability Studies
The test is also performed during process validation or stability studies to confirm preservative performance over time.
Often included in real-time and accelerated stability programs (e.g., at 0, 3, 6, 12 months, etc.) to ensure the preservative remains effective throughout the product’s shelf life.
Purpose: To demonstrate that the preservative remains effective throughout storage.
3. During Routine Production (Batch Testing)
AET is not required for every production batch.
Once the formulation and preservative system are validated and proven stable, routine AET testing for each batch is not necessary.
However, periodic revalidationor confirmation testing may be performed in the following cases:
You must re-do the test when:
-There is a change in preservative, concentration, or formulation composition.
-There is a change in raw material source (especially affecting pH, viscosity, or water content).
-There is a change in container–closure system or packaging material.
-There is a significant deviation in manufacturing or contamination trend.
-The product undergoes reformulation or scale-up.
Purpose: To reconfirm that preservative effectiveness has not been affected by any change.
4. Retesting Frequency / Review
As per GMP and ICH Q10 (Pharmaceutical Quality System), preservative efficacy should be reviewed periodically, typically:
Every 2–3 years, or
Whenever there is a major change control affecting product composition or manufacturing.
Purpose: To maintain continued compliance and product safety assurance.
Summery Table : When to Perform the Test?
| Stage | Requirement | Frequency / Condition | Remarks |
| Formulation Development | Mandatory | Once per new formulation | To select and justify preservative system |
| Process Validation | Mandatory | Initial validation | To prove preservative effectiveness in final product |
| Routine Production | Not required for every batch | Only when formulation, preservative, or packaging changes | Uses previously validated preservative data |
| Stability Studies | Recommended | At different stability time points | Ensures preservative remains effective during shelf life |
| Revalidation | Conditional | Every 2–3 years or after change control | Maintains compliance and assurance of microbial safety |
5. Environmental Monitoring (EM)
What is Environmental Monitoring Test (EM)?
Environmental Monitoring (EM) is a systematic program used in pharmaceutical manufacturing facilities—especially in aseptic processing areas—to assess and control the microbiological and particulate quality of the manufacturing environment.
It ensures that the environment remains within established cleanroom standards (Grade A–D) as required by WHO, EU-GMP, and ISO 14644 guidelines.
Purpose
-The purpose of Environmental Monitoring is to:
-Verify that cleanroom controls(HVAC, air filtration, disinfection, gowning, etc.) are effective.
-Detect any microbial or particulate contamination that could affect product quality.
-Ensure compliance with regulatory limits for viable and non-viable particles.
-Provide trend data to identify potential risks and take corrective actions before contamination occurs.
-Maintain a state of continued process control as per GMP and QMS principles.
Tests Included
Environmental Monitoring consists of both viable (microbiological) and non-viable (particulate) tests.
A. Viable Monitoring (Microbial Load)
Air Sampling (Active Air Sampling)
-Equipment: Air sampler (e.g., sieve or slit-to-agar type)
-Media: Tryptic Soy Agar (TSA)
-Measured as: CFU/m³ (Colony Forming Units per cubic meter)
Settle Plate Method (Passive Air Sampling)
– SOP for Settle Plate of Environmental Monitoring
-Petri plates with TSA are exposed for 4 hours in critical areas.
-Measured as: CFU/4 hours/plate
Surface Monitoring (Contact Plates or Swab Test)
-Used to test surfaces of workbenches, equipment, and walls.
-Media: TSA (for bacteria), SDA (for fungi)
-Measured as: CFU/25 cm²
Personnel Monitoring (Finger Dab or Gown Swab)
-Checks the microbial contamination on operator’s gloves or gown.
-Performed after critical operations.
-Measured as: CFU/finger or CFU/swab area
B. Non-Viable Monitoring (Particulate Load)
Airborne Particle Count
-Instrument: Laser particle counter
-Measures particles ≥0.5 µm and ≥5.0 µm
-Ensures compliance with ISO Class limits.
Differential Pressure Monitoring
-Confirms proper air pressure cascade between cleanroom grades.
Temperature and Humidity Monitoring
-Recorded continuously to maintain suitable environmental conditions.
Guidelines and References
Environmental Monitoring is regulated under several global standards:
| Regulatory Body | Reference / Guideline |
| WHO | WHO Technical Report Series No. 1019, Annex 2 |
| EU-GMP | Annex 1 – Manufacture of Sterile Medicinal Products |
| US FDA | Guidance for Industry – Sterile Drug Products Produced by Aseptic Processing (2004) |
| ISO | ISO 14644-1 & ISO 14644-2 – Cleanroom Classification and Monitoring |
| USP | <1116> – Microbiological Control and Monitoring of Aseptic Processing Environments |
| PIC/S | PE 009-17, Annex 1 – Environmental and Process Monitoring |
Importance
-Ensures product sterility assurance and GMP compliance.
-Detects early signs of contamination, preventing costly batch failures.
-Provides evidence of aseptic control during regulatory inspections (FDA, WHO, EMA).
-Supports risk-based decision making under ICH Q9 (Quality Risk Management).
-Ensures continuous validation of cleanroom and HVAC performance.
When to Perform the Test?
| Type of Monitoring | Frequency / Schedule | Guideline Reference | Purpose / Rationale |
| Active Air Sampling | – Grade A/B: Daily or every production batch – Grade C: Weekly – Grade D: Monthly |
EU-GMP Annex 1 (2022); WHO TRS 1019 Annex 2; USP <1116> | To determine the number of viable microorganisms present in the air and confirm that aseptic conditions are maintained. |
| Settle Plates (Passive Air Sampling) | – Exposed throughout each aseptic operation (usually 4 hours exposure) – Replace between shifts or after 4 hours |
EU-GMP Annex 1 (2022); WHO TRS 1019 Annex 2 | To detect microbial contamination settling by gravity on exposed product or work surfaces during processing. |
| Surface Monitoring (Swab or Contact Plate Method) | – Grade A/B: Daily (after each operation) – Grade C/D: Weekly or as per risk assessment |
USP <1116>; EU-GMP Annex 1 (2022) | To verify that critical surfaces, equipment, and workbenches remain microbiologically clean. |
| Personnel Monitoring (Finger Dab / Gown Swab) | – After completion of each aseptic operation or batch – Especially in Grade A/B areas |
WHO TRS 1019 Annex 2; EU-GMP Annex 1; USP <1116> | To assess operator hygiene and aseptic practices; ensures personnel are not a source of contamination. |
| Non-Viable Particle Monitoring (Particulate Count) | – Grade A: Continuous monitoring during all aseptic operations – Grade B/C/D: At least once per operation or shift |
ISO 14644-1 & 2; EU-GMP Annex 1 (2022) | To measure airborne particulate cleanliness and ensure compliance with cleanroom classification limits. |
| Differential Pressure, Temperature, and Humidity | – Continuous automated monitoring with alarm system – Data reviewed daily |
ISO 14644-2; WHO TRS 1019 Annex 2 | To maintain proper air pressure cascade and environmental control; ensures HVAC system performance. |
| Trending and Data Review | – Monthly for routine trending – Annually for comprehensive review and CAPA analysis |
WHO TRS 1019 Annex 2; EU-GMP Annex 1; ICH Q10 | To evaluate long-term data, identify trends, detect potential contamination sources, and support continuous improvement. |
Notes:
Grade A: Critical zone where sterile products or components are exposed (e.g., filling area).
Grade B: Background environment for Grade A operations.
Grade C/D: Less critical areas where non-sterile processing or preparation takes place.
All monitoring data should be recorded, trended, and reviewed as part of the Environmental Monitoring Program (EMP) under the site’s Quality Management System (QMS).
Any alert or action level excursions should trigger immediate investigation and Corrective and Preventive Action (CAPA).
Acceptable Limits (Typical Examples)
| Cleanroom Grade | Airborne Microbial Limit (CFU/m³) | Settle Plate (CFU/4hr) | Surface (CFU/25 cm²) | Personnel (CFU/glove) |
| Grade A | <1 | <1 | <1 | <1 |
| Grade B | 10 | 5 | 5 | 5 |
| Grade C | 100 | 50 | 25 | 25 |
| Grade D | 200 | 100 | 50 | 50 |
(Based on EU-GMP Annex 1 and WHO TRS 1019 Annex 2)
6. Water Microbiological Testing in Pharmaceuticals
What Is This?
Water Microbiological Testing is the process of analyzing water used in pharmaceutical manufacturing to ensure it is free from harmful microorganisms and meets strict quality standards. Since water is a key component in many pharmaceutical products — including injections, oral solutions, creams, and cleaning processes — its microbial quality directly affects the safety, efficacy, and stability of the final product.
This testing checks for:
-Total bacterial count (to measure overall microbial contamination)
-Fungal contamination (yeasts and molds)
-Specific harmful microorganisms (e.g., E. coli, Pseudomonas aeruginosa, coliforms)
-Endotoxins (for water used in sterile products)
Purpose
The primary purpose of water microbiological testing is to ensure that water used in pharmaceutical production — including Purified Water (PW), Water for Injection (WFI), and Reverse Osmosis (RO) water — is free from harmful microorganisms and meets regulatory quality standards. Water is a critical component in many formulations, and microbial contamination can directly affect product safety, stability, and efficacy.
Objectives include
-Ensuring the water meets microbiological quality limits.
-Detecting potential contamination in the water system.
-Verifying the effectiveness of water purification and sanitization processes.
Tests Included
The common microbiological tests performed on water are:
-Total Aerobic Microbial Count (TAMC) – Counts the total number of aerobic bacteria.
-Total Yeast and Mold Count (TYMC) – Detects fungal contamination.
Specific Pathogen Testing – Detects objectionable microorganisms, e.g.:
-Escherichia coli
-Pseudomonas aeruginosa
Total coliforms
Endotoxin Test (Bacterial Endotoxin Test, BET) – Detects endotoxins from Gram-negative bacteria, especially important for WFI.
Guidelines and References
Water microbiological testing must comply with international regulatory guidelines, including:
| Regulatory Body | Reference / Guideline |
| USP <1231> | Water for Pharmaceutical Use |
| EP 2.6.12 | Microbiological Examination of Water |
| WHO TRS 1025 Annex 7 | Quality Control of Pharmaceutical Water |
| FDA Guidance for Industry | Sterile Drug Products Produced by Aseptic Processing |
| ISO 11731 / ISO 19458 | Microbiological methods for water testing (for industrial reference) Environments |
Importance
-Patient Safety: Prevents water-borne infections and pyrogenic reactions.
-Product Quality: Ensures formulations are not contaminated by microorganisms.
-Regulatory Compliance: Required under GMP and pharmacopoeial standards.
-Process Verification: Confirms the efficiency of water purification and storage systems.
When to Perform the Test?
The frequency of water microbiological testing depends on water type and regulatory requirements:
| Water Type | Test Type | Frequency |
| Purified Water (PW) | TAMC, TYMC, specific pathogens | At least weekly or per batch in critical use |
| Water for Injection (WFI) | TAMC, endotoxin, specific pathogens | Daily in continuous use or per batch |
| RO Water / Other Production Water | TAMC, TYMC | Weekly or monthly depending on usage |
| After system maintenance, sanitization, or repair | All relevant microbiological tests | Immediately after completion |
Note: Critical-use water in sterile product manufacturing requires more frequent monitoring (e.g., daily), while water for cleaning purposes may be tested less frequently.
7. Bioburden Test
What is Bioburden Test?
Bioburden test is a microbiological test that determines the number of viable microorganisms present in raw materials, in-process materials, or bulk pharmaceutical products before sterilization. It is essential for assessing the microbial load in products that will undergo sterilization or further processing.
Purpose
-To quantify the microbial load present in non-sterile starting materials or intermediates.
-To assess the efficiency of sterilization processes (steam sterilization, filtration, or dry heat).
-To identify potential contamination sources in manufacturing processes.
-To ensure that the microbial level is within acceptable limits before final product sterilization.
Tests Included
–Total Aerobic Microbial Count (TAMC): Detects and counts aerobic bacteria.
–Total Yeast and Mold Count (TYMC): Detects and counts fungi.
–Detection of Specified Microorganisms (if required): Such as E. coli, S. aureus, or P. aeruginosa, depending on product type.
Guidelines and References
–USP <61> – Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests
–USP <62> – Tests for Specified Microorganisms
–European Pharmacopoeia (EP) 2.6.12 – Microbiological Examination of Non-Sterile Products
–ISO 11737-1 – Sterilization of Medical Devices: Microbiological Methods
–WHO TRS 1025, Annex 7 – Quality Assurance of Sterile Products
Importance
-Ensures that sterilization processes are effective in eliminating microbial contamination.
-Prevents microbial contamination in final products, ensuring patient safety.
-Helps identify contamination sources in raw materials, production lines, or equipment.
-Supports compliance with GMP, ISO, and regulatory standards.
When to Perform the Test?
Here’s a table format for the Bioburden Test schedule including guidelines and references:
| Material / Stage | When to Perform | Frequency / Time Period | Guidelines / References | Notes |
| Raw Materials | Before use in manufacturing | Each batch of material | USP <61>, EP 2.6.12, WHO TRS 1025 Annex 7 | Ensures incoming materials are within microbial limits before processing |
| In-Process Materials / Bulk Solutions | Before sterilization or aseptic processing | Each batch intended for sterilization | USP <61>, EP 2.6.12, ISO 11737-1 | Helps validate sterilization efficiency |
| Finished Sterile Products | Only if pre-sterilization bioburden data is required | As needed for validation or regulatory requirement | USP <71>, EP 2.6.1 | Not routine for every batch; mainly used for process validation |
| During Process Validation | To establish baseline microbial levels | Once during validation studies | USP <61>, ISO 11737-1 | Provides reference data to set bioburden limits for routine production |
8. Growth Promotion Test (GPT)
What is GPT?
The Growth Promotion Test (GPT) is a quality control test performed on microbiological culture media to confirm that the media can support the growth of microorganisms. This ensures that the media are suitable for performing microbial testing, such as sterility testing, microbial limit tests, and preservative efficacy tests.
In other words, GPT validates the media’s ability to sustain microbial growth, ensuring reliable and accurate test results.
Purpose
-To verify that the microbiological media are capable of supporting growth of selected microorganisms.
-To ensure the media batch is fit for intended microbial testing.
-To maintain the reliability and credibility of microbiological test results.
Tests Included
The GPT is performed using known reference microorganisms, such as:
| Microorganism | Typical Media Tested |
| Bacillus subtilis | Tryptic Soy Agar/Broth, Soybean Casein Digest Medium |
| Staphylococcus aureus | Tryptic Soy Agar/Broth |
| Escherichia coli | Nutrient Agar/Broth, Tryptic Soy Agar |
| Pseudomonas aeruginosa | Nutrient Agar/Broth |
| Candida albicans | Sabouraud Dextrose Agar/Broth |
| Aspergillus brasiliensis | Sabouraud Dextrose Agar |
The number and type of microorganisms used depend on the type of media and intended testing.
Guidelines and References
USP <61> – Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests
USP <62> – Microbiological Examination of Non-Sterile Products: Tests for Specified Microorganisms
EP 2.6.12 – Microbiological Examination of Non-Sterile Products: Microbial Limit Tests
ISO 11133 – Preparation, Production, Storage, and Performance Testing of Culture Media
Importance
-Confirms that all batches of media are capable of supporting microbial growth.
-Detects defective or improperly prepared media, preventing false negative results.
-Ensures regulatory compliance with USP, EP, and ISO standards.
-Critical for product safety testing, as media failure could result in undetected contamination.
When to Perform Growth Promotion Test (GPT)
| Situation / When to Perform | Description / Reason | Test Type (Media involved) | Frequency / Timing | Guideline Reference |
| 1. On receipt of each new batch of culture media | To confirm that each batch of media supports the growth of microorganisms | All solid and liquid media (e.g., TSA, SDA, FTM, SCDM) | Each batch of prepared or purchased media before use | USP <61>, <62>, <71>, EU-GMP Annex 1, WHO TRS 961 Annex 6 |
| 2. After preparation of in-house media | To verify media prepared in the lab is correctly sterilized and supports microbial growth | In-house prepared media | Every batch prepared in-house | USP <61>, WHO TRS 961 |
| 3. For commercially prepared (ready-to-use) media | Even commercial media must be verified for growth support | Ready-made plates, broths, or tubes | Each batch or shipment before use | USP <61>, Ph. Eur. 2.6.12 |
| 4. After transport or long-term storage of media | Transportation or storage may affect media performance | Stored or transported media | If storage condition deviation or >1 month old | USP <61>, Annex 1 (2022) |
| 5. For each new shipment of dehydrated culture media (DCM) | Quality may vary between DCM lots | Dehydrated media | Each new lot before use | Ph. Eur. 2.6.12, WHO TRS 961 |
| 6. When new sterilization or media preparation equipment is validated | To confirm the sterilizer or dispenser is not affecting media quality | All media types | Once during qualification | EU-GMP Annex 15, USP <1227> |
| 7. During method validation (e.g., bioburden, sterility, environmental tests) | To prove media used for recovery is valid for test method | Specific media per test | During each method validation | USP <61>, <62>, <71> |
| 8. After any media reformulation or supplier change | To confirm new composition or supplier media supports growth | Any changed media | First batch from new supplier | USP <61>, Ph. Eur. 2.6.12 |
| 9. When recovery failures occur in routine testing | Investigation of invalid / no-growth results | Specific media involved | As part of root cause investigation | WHO TRS 961, Annex 1 |
Guidelines and References
USP <61>: Microbial Enumeration Tests
USP <62>: Tests for Specified Microorganisms
USP <71>: Sterility Tests
USP <1227>: Validation of Microbial Recovery from Pharmacopeial Articles
EU-GMP Annex 1 (2022): Manufacture of Sterile Medicinal Products
Ph. Eur. 2.6.12: Microbiological Examination of Non-sterile Products
WHO TRS 961, Annex 6: GMP for Sterile Pharmaceutical Products
9. Disinfectant Efficacy Test
What is this?
Disinfectant Efficacy Test (DET) evaluates the effectiveness of disinfectants used in the manufacturing environment against microbial contamination on surfaces, equipment, and sometimes in-use solutions.
It ensures that cleaning and disinfection procedures maintain cleanroom sterility and compliance with GMP standards.
Purpose
-To verify the antimicrobial potency of disinfectants against bacteria, fungi, and spores.
-To ensure cleaning and disinfection procedures reduce microbial load below acceptable limits.
-To prevent contamination of critical areas, equipment, and products.
-To comply with regulatory guidelines (WHO, EU-GMP, USP, ISO 14644).
Tests Included
| Test Type | Description |
| In-use / Use-dilution Test | Disinfectant is tested at working concentration on target microorganisms. |
| Suspension Test | Microbes are suspended in disinfectant solution; log reduction of CFU is measured. |
| Surface Challenge Test | Disinfectant applied on pre-contaminated surfaces; recovery of surviving microbes measured. |
| Contact Time Verification | Confirms that recommended contact time is sufficient to achieve required microbial kill. |
| Neutralization Control | Ensures that disinfectant residues do not inhibit recovery of microorganisms during testing. |
Guidelines and References
USP <1072>: Disinfectants and Antiseptics
USP <1072> / <61> & <62>: Microbial enumeration recovery for disinfectants
EU-GMP Annex 1 (2022): Sterile Medicinal Products – Cleaning and Disinfection
WHO TRS 961, Annex 6: GMP for Sterile Products – Cleaning and Disinfection
ISO 846: Plastics and surfaces – Microbial testing
ASTM E1054 / E2197: Quantitative surface disinfectant efficacy testing
Importance
-Confirms that disinfectants in use are effective and prevent contamination.
-Detects loss of disinfectant potency due to storage, dilution, or expiration.
-Provides evidence for cleaning validation and GMP compliance.
-Ensures safety of critical products (sterile injectables, ophthalmic products).
When to Perform the Test?
| Situation / When to Perform | Description / Reason | Frequency / Schedule | Guideline Reference |
| Before introduction of a new disinfectant | To verify initial effectiveness before routine use | Once per new disinfectant before implementation | USP <1072>, EU-GMP Annex 1 |
| When changing disinfectant concentration or formulation | To ensure modified concentration or formulation still meets efficacy | Every change in formulation or dilution | USP <1072> |
| When changing supplier or manufacturer of disinfectant | To confirm performance equivalence | Each new supplier / brand | WHO TRS 961, Annex 6 |
| Annually (Periodic revalidation) | To ensure long-term performance and resistance check | Once per year | EU-GMP Annex 1 (2022) |
| After major contamination incident or cleaning failure | To confirm disinfectant remains effective after microbial deviation | As part of investigation (OOS/OOT) | WHO TRS 961 |
| During new facility or area qualification | To validate disinfectants under new environmental conditions | Once during area qualification | ISO 14698-1 |
| When introducing new surface material or equipment | Different surfaces may affect disinfectant performance | Once for each new surface type | ASTM E1153 |
| When introducing new environmental isolates (high resistance) | Environmental monitoring may recover resistant strains | As needed (risk-based) | USP <1072>, Annex 1 |
Acceptance Criteria
| Parameter | Requirement | Reference |
| Log reduction | ≥ 3 log10 reduction (≥ 99.9%) for vegetative bacteria; ≥ 2 log10 for spores | USP <1072>, ASTM E2614 |
| Neutralizer validation | Must demonstrate neutralizer is effective and non-toxic | USP <1227> |
| Replicates | Minimum 3 replicates per organism per surface | GMP Standard Practice |
10. Identification of Microorganisms
What is this?
Identification of microorganisms is a laboratory procedure used to determine the exact genus and species of microorganisms isolated from pharmaceutical raw materials, in-process samples, finished products, or environmental monitoring (air, surfaces, water, personnel).
This is done after microbial enumeration (bioburden or environmental counts) to confirm whether the organisms are harmless, expected environmental flora, or potentially pathogenic contaminants.
Purpose
-To verify the type of microorganism present in a product or environment.
-To determine contamination source, whether it is environmental, raw material, equipment, or personnel.
-To support regulatory compliance with pharmacopoeial and GMP requirements.
-To assess risk to product quality and patient safety.
-To support investigations in case of deviations, sterility failures, or environmental excursions.
Tests Included
Microorganism identification generally includes:
| Test Type | Purpose / Notes |
| Gram Staining | Differentiates Gram-positive and Gram-negative bacteria; gives preliminary classification |
| Morphological Examination | Colony morphology on agar, cell shape, arrangement |
| Biochemical Tests | Catalase, oxidase, sugar fermentation, urease, nitrate reduction, etc. |
| Selective / Differential Media | Isolation and presumptive identification (e.g., MacConkey agar for Enterobacteriaceae, Sabouraud for fungi) |
| Automated Systems / API Strips | Rapid identification of bacteria/fungi to species level |
| Molecular Methods (optional) | PCR, 16S rRNA sequencing for confirmation, especially for regulatory or investigation purposes |
Guidelines and References
USP <62>: Tests for Specified Microorganisms
USP <1113>: Identification of Microorganisms
Ph. Eur. 2.6.13: Identification of Microorganisms
WHO TRS 961, Annex 6: GMP for sterile products, microbial identification requirements
EU-GMP Annex 1 (2022): Microbiological monitoring and identification in sterile product manufacture
ICH Q7: Good Manufacturing Practice Guidance for APIs
Importance
-Confirms the identity of microbial contaminants to ensure product safety.
-Helps trace contamination source and implement corrective actions.
-Supports regulatory submissions, deviation reports, and CAPA documentation.
-Distinguishes between normal environmental flora and pathogenic microorganisms.
When to Perform the Test?
| Situation | When to perform | Guideline Reference |
| After bioburden test | If microbial growth is detected in raw material, in-process, or finished product | USP <62>, Ph. Eur. 2.6.13 |
| Environmental monitoring (EM) excursions | When CFU counts exceed alert or action limits in critical areas | WHO TRS 961, EU-GMP Annex 1 |
| Sterility test failures | Immediately after detection of a sterility failure or invalid result | USP <71>, EU-GMP Annex 1 |
| New isolate identification | Whenever an unexpected organism is recovered from raw materials, production, or water system | USP <62>, ICH Q7 |
| Validation or training purposes | Periodically during method validation or proficiency testing | USP <1113>, WHO TRS 961 |
| Regulatory requirement | As required by audit or regulatory inspection | WHO, EU-GMP Annex 1 |
Why Microbiological Testing is Important in Pharmaceuticals
-Ensures product safety, efficacy, and quality.
-Prevents product recalls and regulatory non-compliance.
-Protects patients from infections and toxic reactions.
-Maintains regulatory compliance with WHO, FDA, and EU-GMP standards.
-Supports continuous improvement under the Quality Management System (QMS).
Key Regulatory References
-WHO Technical Report Series 1025 (Annex 7)
-USP <51>, <61>, <62>, <71>, <85>, <1072>, <1116>
-European Pharmacopoeia (EP) 2.6.1, 2.6.12, 2.6.13, 2.6.14
-ICH Q6A, EU-GMP Annex 1, ISO 11737-1, ISO 14698
Conclusion
Microbiological testing forms the foundation of pharmaceutical quality assurance. By implementing robust microbiological control programs — from raw materials to final packaging — pharmaceutical manufacturers can ensure that every product reaching patients is safe, pure, and compliant with international standards.